Document:

Exhibit 10.1

 

LICENSE AGREEMENT

 

This LICENSE AGREEMENT (“Agreement”),
effective as of October [26] , 2003, (the “EFFECTIVE DATE”) by and between PIEZO-TOP LTD, private company
no. 51-[248336-3] a lawfully incorporated Israeli private company with its principal offices located at 47 Hataasiah St. Tel-Hanan,
Israel (“PIEZO-TOP”), PMG MEDICA LTD, private company no 51-280771-0, a lawfully incorporated Israeli
private company with its principal offices located at 47 Hataasiah St. Tel-Hanan, Israel (“PMG”) and NANO-VIBRONIX
INC. a lawfully incorporated Delaware company with its principal offices located at [Cedarhurst, NY] USA (“NANO-VIBRONIX”).

 

RECITALS

 

WHEREAS P.M.G. and PIEZO-TOP are medical
technology companies, and are engaged, among other businesses, in developing piezoelectric systems for medical applications;

 

WHEREAS NANO-VIBRONIX is a medical technology
company

 

WHEREAS, P.M.G. and PIEZO-TOP have developed
technology which is applicable to bio-film prevention in the human body.

 

WHEREAS, P.M.G. and PIEZO-TOP are interested
in licensing the Technology to NANO-VIBRONIX, and NANO-VIBRONIX is interested in the exclusive licensing rights to the TECHNOLOGY
from PMG and PIEZO-TOP for the worldwide commercialization thereof; and

 

WHEREAS, subject to the terms and conditions
set forth in this Agreement, NANO-VIBRONIX wishes to obtain and PMG and PIEZO-TOP are willing to grant an exclusive license under
which the know-how and intellectual property rights related to the TECHNOLOGY will be used by NANO-VIBRONIX in order to proceed
with the commercialization thereof;

 

NOW, THEREFORE, the Parties hereto, intending
to be legally bound, hereby agree as follows:

 

ARTICLE 1 — DEFINITIONS

 

In this Agreement, the following expressions
shall bear the meanings set forth along side them:

 

“LICENSED TECHNOLOGY”
shall mean all past, present and future tangible or intangible know-how, (whether or not patentable), data, products, processes,
articles of manufacture, information, software (including source code and object code embodiments), hardware, algorithms, techniques,
designs, and any other tangible or intangible technical materials or information (collectively, the “KNOW-HOW”),
which has been developed or acquired by PMG and PIEZO-TOP to the extent such KNOW-HOW is reasonably necessary or useful
for the manufacture, use, or sale of products and technology related to bio-film prevention in the human body or other medical
purposes (which shall be deemed to include without limitation: biofilm prevention in indwelling catheters, biofilm prevention in
dialysis and respiratory assist devices and control of bacteria in the hospital and outpatient environments by biofilm prevention
and killing of bacteria) provided that KNOW-HOW which has been developed or acquired more than 5 years after the Effective
Date shall not be included in “LICENSED TECHNOLOGY”. To avoid any doubt, the LICENSED TECHNOLOGY does
not include any application, which is related to water treatment or purification, even in the hospital and outpatient environments.

 

    	 

    	 

    

 

“IP RIGHTS” shall mean
unpatented inventions, patent applications, patents, design rights, copyrights (including, without limitation, rights in computer
software), know-how and other trade secret rights, and all other intellectual property rights and rights or forms of protection
of a similar nature or having equivalent or similar effect to any of these rights, whether or not any of these rights is registered,
and including, without limitation, applications for registration of, and rights to apply for, any such rights.

 

“USD” shall mean United
States Dollars or the equivalent amount thereto in New Israeli Shekels according to the representative rate published by the Bank
of Israel and known on date of payment.

 

“SUBSIDIARY” shall mean
a corporation, company or other entity:

 

		(a)	more than fifty percent (50%) of whose outstanding shares or securities (representing the right
to vote for the election of directors or other managing authority) are, now or hereafter, owned or controlled, directly or indirectly,
by a party hereto, or

 

		(b)	which does not have outstanding shares or securities, as may be the case in a partnership, joint
venture or unincorporated association, but more than fifty percent (50%) of whose ownership interest representing the right to
make the decisions for such corporation, company or other entity is now or hereafter, owned or controlled, directly or indirectly,
by a party hereto, but such corporation, company or other entity shall be deemed to be a Subsidiary only so long as such ownership
or control exists.

 

ARTICLE 2 - REPRESENTATIONS

 

		2.1	The preamble and definitions to this Agreement are an integral part thereof.

 

		2.2	PMG and PIEZO-TOP represent and warrant that they have the full right and power to grant the license
set forth in this Agreement.

 

		2.3	NANO-VIBRONIX hereby acknowledges that

 

(One)PMG and PIEZO-TOP exclusively
own all right, title and interest in and to the LICENSED TECHNOLOGY, and

 

(Two)PMG and PIEZO-TOP otherwise reserve
all rights to the KNOWHOW except those specifically granted to NANO-VIBRONIX herein.

 

		2.4	Each party represents and warrants that it is a corporation in good standing under the laws of
the country of its incorporation; that it has the authority to enter into this Agreement; that it has obtained all corporate approvals
necessary to enter into this Agreement; and that this Agreement is valid and binding and enforceable against it in accordance with
its terms.

 

    	2

    	 

    

 

		2.5	PMG and PIEZO-TOP (“LICENSORS”) further represent and warrant that:

 

		(a)	the LICENSORS have all right, title, and interest in the LICENSED TECHNOLOGY;

 

		(b)	the LICENSORS have taken reasonable security measures, including measures against unauthorized
disclosure, to protect the secrecy, confidentiality and value of the LICENSED TECHNOLOGY. No employee, consultant (paid or unpaid),
director or shareholder of the LICENSORS, or any present or past employer of any such person, has any right with respect to the
KNOWHOW and IP Rights licensed hereunder. Each of the LICENSORS' employees, consultants (paid or unpaid), and any other persons
who, either alone or in concert with others, developed, invented, discovered, derived, programmed or designed KNOWHOW and IP Rights
licensed hereunder, or who has knowledge of or access thereto have entered into written confidentiality agreements and invention
assignment agreements assigning to the LICENSORS all such IP Rights.

 

		(c)	to the best of the LICENSORS' knowledge, the use of the KNOWHOW and IP Rights licensed hereunder
and any other IP Rights necessary to enable operation of the business of NANO-VIBRONIX as currently conducted and/or proposed to
be conducted, shall not constitute an infringement, misappropriation or misuse of any intellectual property rights or other rights
of any third party.

 

		(d)	Aside from the M. Weiss case, none of the LICENSORS are aware of any claims alleging that any of
the LICENSORS has violated any of the patents, copyrights, trade secrets or other proprietary rights of any other person or entity.
None of the LICENSORS or their employees is obligated under any contract (including licenses, covenants or commitments of any nature)
or subject to any judgment, decree or order of any court or administrative agency that would interfere with such person's efforts
to promote the development of the LICENSED TECHNOLOGY.

 

		(e)	the LICENSORS have not granted, and shall not grant, any third party any rights, nor taken upon
themselves obligations towards third parties, inconsistent with the License or any of LICENSORS' obligations herein.

 

		2.6	Each and every obligation taken by the Parties to this Agreement will be deemed taken on the party's
own behalf as well as on its Subsidiaries' behalf to the extent that such Subsidiaries exist.

 

ARTICLE 3 - GRANTS OF LICENSES

 

		3.1	PMG and PIEZO-TOP hereby grant to NANO-VIBRONIX, and NANO-VIBRONIX hereby accepts, subject to the
terms and conditions set forth in this Agreement, a perpetual, exclusive, worldwide license to make any and all use of the LICENSED
TECHNOLOGY and all IP Rights related to the LICENSED TECHNOLOGY, including without limitation the right to make, have made, use,
modify, distribute, create derivative works and sublicense (the “LICENSE”) provided that only to the extent that NANO-VIBRONIX
and/or its Subsidiaries have paid the price for the TECHNOLOGY then due to PMG and PIEZO-TOP under this Agreement.

 

		3.2	Notwithstanding the generality of Section 3.1 hereof, the LICENSE, as of the date hereof, includes,
without limitation, the patents, patent applications and provisional patent applications listed in Appendix “A” hereto
and the KNOW HOW listed in Appendix “B” hereto.

 

    	3

    	 

    

 

		3.3	The LICENSORS shall immediately begin an orderly transfer of all of the LICENSED TECHNOLOGY to
NANO-VIBRONIX and shall promptly provide (and create if necessary) all drawings, manuals, specifications and formulas, any proprietary
manufacturing equipment or apparatus, as well as any demonstrations and training, which are necessary or useful for the exploitation
of the LICENSED TECHNOLOGY.

 

		3.4	All new inventions of LICENSORS, which may constitute LICENSED TECHNOLOGY, shall be immediately
disclosed to NANO-VIBRONIX.

 

		3.5	LICENSORS shall file and prosecute the patent applications
listed in Appendix B (with respect to existing LICENSED TECHNOLOGY) and all patent applications with respect to new inventions
of LICENSORS, which may constitute LICENSED TECHNOLOGY. LICENSORS shall consult with NANO-VIBRONIX in regard to the preparation
and prosecution of such patent applications.Notwithstanding the foregoing, NANO-VIBRONIX may elect to file and/or prosecute
any patent application with respect to LICENSED TECHNOLOGY.

 

		3.6	LICENSORS shall execute all documents, join in any action and provide all cooperation requested
by NANO-VIBRONIX necessary or useful for the full exploitation of the License, including without limitation, any patent filing
and prosecution, registration of the License, any action with respect to the infringement of the LICENSED TECHNOLOGY and claims
of infringement against NANO-VIBRONIX with respect to the LICENSED TECHNOLOGY. In the event that NANO-VIBRONIX shall prosecute
a claim of infringement of the LICENSED TECHNOLOGY against third parties, then without prejudice to any other rights hereunder,
NANO-VIBRONIX shall retain all of the proceeds of such claim.

 

		3.7	Without prejudice to any of LICENSORS' other obligations hereunder, LICENSORS shall defend, indemnify,
and hold NANO-VIBRONIX and/or its officers, directors, agents, shareholders and representatives harmless from and against, and
will solely and exclusively bear and pay, any and all claims, suits, losses, penalties, settlements, damages (whether actual, punitive,
consequential, or otherwise) and all liabilities and the associated costs and expenses (including attorneys' fees) arising out
of any claim that may arise. Piezotop will indemnify and hold harmless regarding the claim that Menachem Weiss has brought or towards
any settlement that may be reached with him that which shall affect the KNOWHOW, the LICENSED TECHNOLOGY or the LICENSE.

 

ARTICLE 4 - PAYMENTS AND REPORTS

 

		4.1	For the rights granted and obligations undertaken under this Agreement, NANO-VIBRONIX shall pay
PMG and PIEZO-TOP as follows:

 

		4.1.1	14 (fourteen) days after the close of the first round of investment in NANO-VIBRONIX, NANO-VIBRONIX
will pay PMG and PIEZO-TOP, each, a licensing fee of USD 5,000 (five thousand) (the “FIRST Licensing Fee”) (USD 10,000
all together).

 

    	4

    	 

    

 

		4.1.2	No later than 14 (fourteen) days after the second investment in NANO-VIBRONIX, NANO-VIBRONIX will
pay PMG and PIEZO-TOP, each, a second licensing fee of USD 7,500 (seven thousand five hundred) (the “Second Licensing Fee”)
(USD 15,000 all together).

 

		4.1.3	In the event of

 

		(a)	a third investment in NANO-VIBRONIX, or

 

		(b)	a buy-out of more than 40% of NANO-VIBRONIX's stock, or

 

		(c)	an 1P0, and no later than 14 (fourteen) days thereafter (hereinafter, collectively: the Third Investment),

 

NANO-VIBRONIX will pay PMG and PIEZO-TOP,
each, a third licensing fee of USD 25,000 (twenty five thousand) (the “Third Licensing Fee”) (USD 50,000 all together).

 

		4.2	NANO-VIBRONIX shall make written reports to PMG and PIEZO-TOP within 7 (seven) days after each
investment therein.

 

ARTICLE 5 — DEVELOPING OF THE
LICENSED TECHNOLOGY

 

All Parties agree to keep confidential
the LICENSED TECHNOLOGY as provided in the non-disclosure agreement attached to this Agreement as an integral part thereof.

 

ARTICLE 6 - ASSIGNMENT

 

This Agreement and the rights granted in
this Agreement are personal to the parties thereto. Parties shall not have the right to assign rights or obligations in this Agreement.
Notwithstanding the foregoing, NANO-VIBRONIX may assign the rights granted in this Agreement provided the assignee assumes all
rights and responsibilities of the Agreement.

 

ARTICLE 7 - NOTICE

 

		7.1	Any notice required or provided for by the terms of this Agreement shall be in writing. All notices
shall be sent by registered mail to the business address of the party to be given notice. The business addresses of the parties
shall be as follows:

 

PMG Medica Ltd.

47 Hataasiah St. P.O. Box 515

Tel-Hanan, Israel 36603.

 

PIEZO-TOP LTD

47 Hataasiah St. P.O. Box 515

Tel-Hanan, Israel 36603

 

	
        NANO-VIBRONIX INC.

	 
	 
	USA

 

    	5

    	 

    

 

		7.2	Unless otherwise proven, each such notice given by either party hereto shall be deemed to have
been received by the other party on the 10th day following the mailing date.

 

ARTICLE 8 - MISCELLANEOUS

 

		8.1	The construction and performance of this Agreement shall be governed by and shall be subject to
the laws of the State of Israel.

 

		8.2	Neither party shall be deemed to have waived any of its rights under this Agreement by failure
to take any action to enforce any of its rights at any particular time.

 

		8.3	This Agreement is the entire Agreement between the parties and there are no other terms, obligation,
covenants, representation, statements or conditions, oral or otherwise, of any kind except the non-disclosure agreement attached
to this Agreement as an integral part thereof.

 

		8.4	This Agreement may not be changed, modified, or amended in whole or in part except by written document
signed by the duly authorized officers of both parties.

 

		8.5	The provisions of the Agreement shall be deemed separable. A holding by a court of competent jurisdiction
that any provision of this Agreement which is not material to the consideration provided by either party is void or unenforceable
shall not affect the validity or enforceability of the remaining provisions of the Agreement.

 

		8.6	To all payments mentioned in this Agreement there shall be added the appropriate value added tax
(VAT) as regulated on date of payment.

 

ARTICLE 9 - ARBITRATION 

 

		9.1	Any controversy or claim arising under or related to technical disputes regarding the LICENSED
TECHNOLOGY (for instance, if parties disagree on the question if a specific item is included in the licensed technology) shall
be settled by single arbitration jointly agreed upon the parties. The arbitrator will be selected by the parties or by court if
they disagree.

 

		9.2	The arbitrator will be a university professor in physics or engineering, and if such is not selected
by mutual consent then a person with appropriate technical and scientific background will be selected arbitrator (the “Arbitrator”).

 

		9.3	The Arbitrator will be bound by the Israeli Arbitration Act of 1968 and its appendix, but will
have to give a detailed and explained verdict.

 

		9.4	Other disputes, which are not of a technical nature will not be subject to this arbitration clause.

 

IN WITNESS WHEREOF, the parties have MIS
this Agreement to be executed in duplicate to be effective as of [10/26/03]         ]

 

 

	/s/ Jona Zumeris	 	/s/ Jona Zumeris	 	/s/ Harold Jacob
	PMG MEDICA Ltd.	 	PIEZO-TOP LTD.	 	NANO-VIBRONIX INC.

 

    	6

    	 

    

 

CONFIDENTIAL DISCLOSURE AGREEMENT

 

Effective Date: October 26th,
2003

 

To protect certain confidential information
that may be disclosed between them, NanoVibronix Inc., and its affiliates (collectively “NV”), and the “Participant”
identified below, agree that:

 

		1.	Any party to this Agreement may be a Discloser of confidential information.

 

		2.	The parties' primary contacts for disclosing or receiving confidential information are:

 

NV: Harold Jacob MD or other
employees of NV designated in writing and Participant: Piezotop Ltd., PMG Medica Ltd. and all of their employees and Jona Zumeris:

 

		3.	The confidential information (“Information”) that is the subject of this Agreement
is described as:

 

For NV: -LICENSED TECHNOLOGY
AS DESCRIBED IN THE LICENSE AGREEMENT

 

For Participant: LICENSED TECHNOLOGY
AS DESCRIBED IN THE LICENSE AGREEMENT

 

The relationship created under
this Agreement is confidential and is to be treated as Information according to the terms of this Agreement.

 

		4.	This Agreement relates to Information that is disclosed to a party (“Recipient”) after
the Effective Date.

 

		5.	Recipient's duties under this Agreement expire October 15, 2015.

 

		6.	Recipient shall not disclose Information to a third party without express written permission from
Discloser. Recipient shall protect the disclosed Information by using the same degree of care, but no less than a reasonable degree
of care, to prevent the unauthorized disclosure of the Information, as Recipient uses to protect its own confidential information
of a like nature.

 

		7.	If Recipient is required by judicial or administrative process to disclose Information, Recipient
shall promptly notify Discloser and shall allow Discloser a reasonable time to oppose such process.

 

		9.	Recipient's duties under this Agreement shall apply to Information that is (a) disclosed by Discloser
in writing and is marked at the time of disclosure to indicate it is confidential; (b) disclosed by Discloser in any other manner
and is indicated at the time of disclosure to be confidential and thereafter is also summarized and designated as confidential
in a written memorandum delivered to Recipient within one month of the disclosure; or (c) disclosed in the form of tangible materials
transmitted to Recipient with a written memorandum within 30 days indicating the confidential nature of the materials. (d) information
which is obviously sensitive and would be considered confidential

 

    	7

    	 

    

 

		13.	Each Discloser warrants that it has the right to make disclosures under this Agreement.

 

		14.	Except as otherwise provided herein, all additions or modifications to this Agreement must be made
in writing and executed by all parties.

 

		15.	This Agreement constitutes the entire agreement and understanding between the parties hereto relating
to the subject matter hereof. This Agreement shall be deemed made in and shall be governed by the laws of the State of New York,
U.S.A. pertaining to contracts made and performed within that state, without recourse to any conflicts of laws principles and the
State and/or Federal Courts in the State of New York shall have exclusive jurisdiction of any litigation arising under or in connection
with this Agreement. Should any provision of this Agreement not be enforceable in any jurisdiction, the remainder of this Agreement
shall not be affected thereby.

 

In witness thereof, the duly authorized
representatives of the Companies have signed this Agreement as the date, stated below.

 

 

	/s/ Harold Jacob	 	/s/ Jona Zumeris
	
        Harold Jacob MD

        CEO NANO Vibronix INC
	 	
        Jona Zumeris

        PIEZOTOP LtD

	 	 	 
	 	 	 
	/s/ Jona Zumeris	 	 
	Jona Zumeris	 	 
	PMG Medica LtD	 	 

 

    	8Exhibit
10.2

 

License
Agreement

 

between

 

AC Engineering
Ltd.

11 Netivei
Am

Jerusalem,
Israel 97552

 

hereinafter
referred to as

“AC”

 

and

 

NanoVibronix
Inc.

105 Maxess
Road, Suite S124

Melville,
NY 11747

 

hereinafter
referred to as

“NV”

 

    	1

    	 

    

COMPANY CONFIDENTIAL

 

 

This License Agreement (the “Agreement”)
is made and entered into this 11th day of December 2011 (the “Effective Date”) by and between NanoVibronix Inc., located
at 105 Maxess Road, Suite 5124, Melville, NY 11747 , and its affiliates, (“NV”), and AC Engineering Ltd. an Israeli
Company, located at 11 Netivei Am, Jerusalem, Israel 97552 (“AC”).

 

WITNESSETH:

 

Whereas, AC represents that it
has designed and developed a negative pressure wound treatment product which, in part, is based upon concepts contained in Patents
filed by AC and issued by the US Government Patent and Trademark Office and hereinafter listed; and

 

Whereas NV has designed, developed,
and obtained licensing rights to, and/or is in the process of designing, developing , and/or obtaining licensing rights to a wound
treatment ultrasound system, a wound instillation system, and wound oxygenation technology, which can be used together with the
AC negative pressure wound treatment or separately, and

 

Whereas NV desires to obtain
the right, license and privilege to manufacture, use, sell and lease, in the United States, the aforesaid AC product, including
improvements thereon which are made by AC or NV during the term of this Agreement.

 

Now therefore, in consideration
of the mutual agreements herein provided the Parties agree as follows:

 

Article 1: Definitions

 

For the purpose of this Agreement,
the following definitions shall apply:

 

		1.1	‘Canister’ shall mean the negative pressure
wound treatment canister component of the Licensed Product that is covered in whole or part by the Licensed Patent(s) or that
is manufactured using the Know-How.

 

		1.2	‘Contract Year’ shall be each sequential
twelve (12) month period beginning with the first day of the first month immediately after the Effective Date.

 

		1.3	‘Effective Date’ shall mean the date first
set forth above.

 

		1.4	‘Gross Revenues’ shall mean, subject to
the last sentence hereof, sale , rental, or other revenues received by NV, or the fair market value of other consideration received
by NV, in respect of the sale or lease of Pumps, whether sold separately or as part of an Integrated Product. For the avoidance
of any doubt, the term “Gross Revenues” does not include (i) sales tax that NV has to pay or absorb, customs duties,
and transportation and insurance charges, if included in the gross sales price and identified on the relevant invoice, and any
and all Federal, foreign, State or local taxes (except income tax) incurred by NV, if applicable, on such sales; and (2) amounts
refunded or credited for returned goods and fees or commissions paid or payable by NV to distributors. In no event shall the Gross
Revenues per each Pump be calculated as less than US$1,000 regardless of the actual revenues received; provided, however, that
in the event the Pump Components are sold separately, the Gross Revenues per each Pump Component shall be calculated in accordance
with the official NV price list then applicable.

 

    	2

    	 

    

COMPANY CONFIDENTIAL

 

 

		1.5	‘Integrated Product’ shall mean any product
developed by NV that integrates and/or incorporates as a component thereof the Licensed Product, or any portion thereof,. Except
for the Licensed Product, which is part of the Integrated Product, NV shall own all right, title and interest in and to the Integrated
Products.

 

		1.6	‘Know-How’ shall mean the Technical Data
provided by AC to NV and the Technical Cooperation rendered by AC to NV under this Agreement.

 

		1.7	‘Licensed Patent(s)’ shall mean United States
patent number 7,284,965, and/or any other United States patents for any improvements or additions to the ‘Licensed Product’
which are made by AC, as well as additional pending applications as listed in Exhibit D, including all additions, divisions, confirmations,
continuations, continuations-in-part, substitutions, re-issues, re-examinations, extensions, registrations, patent term extensions,
supplementary protection certificates and renewals of any of the above.

 

		1.8	‘Licensed Product’ shall mean the AC negative
pressure wound treatment system consisting of the Canister and the Pump, the electronic circuitry and related software, that is
described in the Licensed Product Specification attached hereto as Exhibit ‘A’, as well as any modifications or improvements
to the Licensed Product made by AC.

 

		1.9	‘Market’ shall mean the United States.

 

		1.10	‘NV Technology’ shall mean NV’s technology,
intellectual property, know-how, and trade secrets that it owns and/or has licensed relating to wound treatment systems. For the
avoidance of any doubt, the NV Technology does not include the Licensed Product nor the Licensed Patent(s).

 

		1.12	‘Pump’ shall mean the negative pressure
wound treatment pump component of the Licensed Product and the Pump Components, that are covered in whole or part by the Licensed
Patent(s) or that are manufactured using the Know-How.

 

		1.13	‘Pump Components’ shall mean the charger,
cradle, tubing, bleed hole system and carrying case components of the Pump.

 

		1.14	‘Support’ shall mean to replace, use, operate,
maintain, repair, assemble, test, calibrate, overhaul, install, and handle the Licensed Product, as well as training and documentation
in respect thereof.

 

		1.15	‘Technical Cooperation’ shall mean technical
information used in the application of the Technical Data to the manufacture and Support of the Licensed Product conveyed by AC
in writing, by verbal communication, or by demonstration or training.

 

    	3

    	 

    

COMPANY CONFIDENTIAL

 

 

		1.16	‘Technical Data’ shall mean the manufacturing
drawings, specifications, material lists, protocols and results, processes, and component specifications, needed for the manufacture
of the Licensed Product.

 

Article 2: Grant to NV

 

		2.1	AC hereby grants to NV during the term of this Agreement
(as set forth in Article 12 below), the following licenses and rights, subject to the limitations of paragraph 2.2 below and all
other terms of this Agreement.

 

		(a)	A non-exclusive right and license to use the Know-How
for the manufacture and/or Support of the Licensed Product for negative pressure wound treatment applications.

 

		(b)	An exclusive right and license to market, sell lease
and/or distribute, whether directly or via dealers, distributors and sales agents, the Licensed Product in and to the Market for
negative pressure wound treatment applications.

 

		(c)	An exclusive right and license to sell and/or provide
in the Market Support for any Licensed Product sold by NV or its dealers to customers pursuant to this Article 2; and

 

		(d)	A non-exclusive right and license, with the right to
sub-license, to design, develop, and implement modifications, improvements, and derivate works of the Licensed Product for negative
pressure wound treatment applications.

 

		(e)	A non-exclusive right and license to integrate and/or
incorporate the Licensed Product with NV products to create Integrated Products, and to market, sell, lease, and/or distribute
such Integrated Products in the Market.

 

		(f)	A license under any and all Licensed Patents insofar
as such license is required to exercise the rights and licenses specified in paragraph 2.1 [a], [b], [c], [d], and [e] of this
Article 2.

 

		2.2	The rights and licenses granted to NV above are limited
to the manufacture, marketing, sale, lease, distribution, and Support of the Licensed Product solely for negative pressure wound
treatment applications, with all other applications and markets being expressly reserved to AC’s exclusive control. NV shall
be entitled to place its markings, logo and/or symbol on the products covered under sub-article 2.1 above. NV shall not be liable
if Licensed Product sold by it for uses permitted to NV hereunder are in fact used subsequently for a different purpose not authorized
by NV.

 

		2.3	NV shall be entitled to grant sublicenses under this
Agreement for purpose of using third-party subcontractors for the purpose of manufacturing, marketing, selling, leasing, distributing
and supporting the Licensed Products, subject to notifying AC of each such sub-license and sub-contract.

 

    	4

    	 

    

COMPANY CONFIDENTIAL

 

 

Article 4: AC Representations
and Warranties

 

		4.1	AC represents as follows:

 

		(a)	That it is the sole owner of all right, title and interest
in and to the ‘Licensed Product’ and the Licensed Patent(s).

 

		(b)	That AC has not granted any, and that there are no outstanding,
options, licenses or agreements of any kind relating to the Licensed Product or the Licensed Patent(s) that conflict with the
rights and licenses granted hereunder;

 

		(c)	That AC has the full right, power and authority to enter
into this Agreement and to grant the rights and licenses herein granted and;

 

		(d)	That AC has received no notice and has no knowledge that
the Licensed Product or the Licensed Patent(s) infringe any intellectual property rights of any third party, including the claims
of any patent or rights of another party.

 

		(e)	That AC has received no notice and has no knowledge of
any existing or threatened litigation concerning the Licensed Product or Licensed Patent(s). AC shall promptly notify NV in writing
upon becoming aware of any threatened litigation challenging the validity of the Licensed Patent(s);

 

		(f)	That there is no pending or threatened interference,
re-examination, opposition or other proceeding or challenge relating to or involving the validity of, scope of, or AC’s
ownership of, the Licensed Patent(s).

 

		4.2	 

 

		(a)	AC warrants that the Know-How to be furnished to NV under
this Agreement, in writing, is identical to the Know-How which AC uses for the manufacture and Support of the Licensed Product,
and shall comprise the know-how required to manufacture and Support the Licensed Product. AC shall correct any non-conformity
with this warranty within thirty (30) days of receiving notice of such non-conformity.

 

		(b)	AC warrants that the Licensed Product will perform substantially
in accordance with the specifications set forth in Exhibit A attached hereto, as same may be modified from time to time by AC
to reflect improvements or other modifications to the Licensed Product.

 

		(c)	Any warranties or other undertakings given by NV to third
parties in respect to the Licensed Product shall in no way obligate AC.

 

		(d)	The warranties detailed in this Article 4.2 are in lieu
of all other warranties, expressed or implied including any implied warranty of merchantability or fitness for a particular purpose.

 

    	5

    	 

    

COMPANY CONFIDENTIAL

 

 

Article 5: Technical Data
and Technical Cooperation

 

		5.1	Within forty-five (45) days of the Effective Date, AC
shall provide NV with all of the Technical Data necessary for NV to manufacture and Support the Licensed Product.

 

		5.2	AC agrees that during the term of this Agreement it
will exercise commercially reasonable efforts to assist NV in implementing the Technical Data provided hereunder. AC will not
receive additional compensation for such assistance, except for pre-approved air fare and accommodation expenses for AC and any
AC personnel or consultants assisting AC in such effort. Any such activity of AC shall be as an independent contractor, and neither
AC nor any such consultants or personnel assisting AC shall be deemed employees of NV for any purpose.

 

		5.3	AC will exercise its commercially reasonable efforts
to design and implement improvements to Licensed Product requested by NV within twelve (12) months of the Effective Date of this
Agreement. Any failure to achieve any such requested improvement shall in no way derogate from the rights and obligations of the
parties hereunder as to the Licensed Product herein originally defined.

 

		5.4	Notwithstanding anything to the contrary herein, NV
is aware that (i) the Pumps and Canisters for the Licensed Product, and their related tooling and Technical Data, may require
additional work and qualification to bring them to full-scale production status, and (ii) specific test equipment for the production
line or multi cavity molds for reducing product cost may be required. NV will undertake all of the above described work at its
own cost and risk, and AC will provide all requested support on the terms of Paragraph 5.2 above, and AC will make the tooling
in its possession available to NV for production of Pumps and Canisters.

 

		5.5	NV agrees to (i) use reasonable commercial efforts to
subcontract the establishment of a production line for the Licensed Product, as soon as practicable, in accordance with Exhibit
B hereto, and (ii) sell to AC Licensed Product manufactured by NV upon AC’s request. The price to AC for such Licensed Product
shall be determined under the terms of Exhibit C hereto.

 

Article 6: Governmental Approvals

 

		6.1	NV will be responsible for obtaining the necessary government
or agency approvals, including without limitation FDA and CE approvals, and will make reasonable commercial efforts to obtain
the approvals required for the manufacture, sale, use and Support of the Licensed Product in the Market. NV shall be responsible
for all costs related to that effort. AC shall, pursuant to the terms of Paragraph 5.2 above, cooperate with NV in obtaining such
approvals. NV will also be responsible for the payment of all expenses associated with the preparation and development of all
materials data and testing necessary for obtaining such approvals. NV shall supply to AC copies of all documentation and/or presentations
submitted or made to the FDA or with respect to the CE approval process within 30 days of their submission or presentation to
the FDA or other related agency. Upon the expiration or termination of this Agreement for any reason other than breach by AC,
NV will assign all of its rights to any such FDA or CE approvals to AC.

 

    	6

    	 

    

COMPANY CONFIDENTIAL

 

 

Article 7: Compensation

 

		7.1	NV shall pay AC (i) a royalty of five percent (5%) on
Gross Revenues as well as (ii) a royalty of seventy cents ($0.70) per Canister sold or leased by NV to a third party.

 

		7.2	As an advance on the payments due to AC under 7.1 above,
NV shall pay AC an advance royalty payment to AC of US$75,000 (seventy-five thousand US dollars) as soon as FDA 510(K) listing
is obtained. From each future royalty payment, NV shall withhold an amount equal to fifty percent (50%) of the royalty payment
until the advance royalty payment is fully recouped. Additionally, if by the end of the initial term of this Agreement (as set
forth in Article 12 below), AC has not received in royalty payments a minimum of US$150,000 then NV will, at the end of said initial
term, pay to AC the difference between US$150,000 and the royalties actually paid.

 

		7.3	The royalties payable under sub-article 7.1 shall be
calculated quarterly [i.e. for the quarterly periods ending on, 31 March, 30 June, 30 September, and 31 December during the term
of this Agreement, relating to the quarters of NV’s business year, starting on January 1 of each year Payment shall be made
within ten (10) days of receipt of an invoice from AC. Within forty-five (45) days of the end of each quarterly period, NV shall
provide AC with a report setting forth the number of units of Licensed Product sold or rented by NV during the preceding quarter
and the Gross Revenues received by NV in said preceding quarter. In the event of a delay in excess of fourteen days in the payment
of any sums due to AC, interest will be due on said late payment to the date of actual payment at a rate of one-half percent (0.5%)
per month from the date on which payment is due [i.e. thirty days after receipt of invoice]. Any delay in payment in excess of
thirty (30) days will be deemed a breach of this Agreement and will entitle AC to terminate this Agreement by written notice to
NV pursuant to Article 12.2[B] below, whereupon the provisions of paragraphs 13.2, 13.3, 13.4, 13.5 and 13.6 of Article 13 below
shall apply. NV will add to all the payments under paragraphs 7.1, 7.2, and/or 7.5 any VAT applicable to such payments.

 

		7.4	NV agrees to keep accurate books of accounts to enable
the royalties payable hereunder to be determined, as well as to determine the manufacturing cost of Licensed Products sold to
AC, and further agrees that such books of accounts shall be available for examination, not more frequently than once in any twelve
(12) month period, by a certified public accountant appointed by AC, during reasonable business hours upon prior reasonable notice,
to the extent necessary to verify the reports, records and payments provided for herein. The public accountant has to be acceptable
to NV. NV shall be required to keep such books of accounts for no less than three (3) years from the time of making them.

 

		7.5	NV shall pay to AC all sums payable under the terms
of this Agreement in US dollars. All payments due by NV to AC shall be made free and clear, and free of any assessments or other
charges; provided, however that NV may deduct from payment any income tax or tax of a similar nature imposed by any governmental
taxing authority on the income of AC from such payment and actually paid by NV for the account of AC, and NV shall furnish to
AC tax withholding certificates as evidence that such tax payments have been made on AC’s behalf to the applicable taxing
authorities.

 

    	7

    	 

    

COMPANY CONFIDENTIAL

 

 

Article 8: Patents

 

		8.1	NV agrees that the ‘Licensed Product’ shall
bear a patent notice as required by the applicable patent numbers relating to the marking of patent articles. AC agrees to advise
NV of the applicable patent numbers. Pending the issuance of any applicable patents, each item of ‘Licensed Product’
or its package will be marked ‘Patent pending’.

 

Article 9: Improvements

 

		9.1	NV may make improvements to the Licensed Product, and
in such case NV shall own all intellectual property rights to such improvements. With regard to Licensed Products manufactured
by NV for AC, any changes made to the Licensed Product or to the tooling are subject to AC’s approval, which approval shall
not be unreasonably withheld or delayed.

 

		9.2	In the event NV makes any improvements to the Licensed
Product, NV will inform AC within thirty (30) days of its implementation by NV and provide a copy of the corresponding data and/or
know-how accordingly. AC shall have the right, at no charge to AC, to obtain a license to use such improvements to the Licensed
Product solely to make, use, sell and lease Licensed Product in the markets reserved to AC hereunder for the Licensed Product
during the term of this Agreement.

 

		9.3	For the avoidance of any doubt, NV shall retain all
right, title, and interest in and to the NV Technology and all NV products designed, developed, or produced using the NV Technology.
Nothing herein shall be construed as granting AC a license to the NV Technology, nor to any products designed, developed or produced
using the NV technology.

 

Article 10: Indemnification

 

		10.1	Indemnification by NV. NV will defend against
any claim by any third party against AC for damages incurred as a result of an injury, illness or death of any person which is
caused by a manufacturing defect in the Licensed Product manufactured and sold by NV, and indemnify AC against all costs, damages,
losses, liabilities and expenses (including attorneys’ fees and costs) awarded against AC by a court of competent jurisdiction,
or agreed to in a written settlement agreement signed by NV arising out of such claim.

 

		10.2	Indemnification by AC. AC will advance fifty
percent (50%) of NV’s defense costs and assist NV’s counsel at NV’s request in the defense of any claim by any
third party against NV that the Licensed Product or the Licensed Patent(s) infringe any intellectual property rights of another,
and in the event of an adverse judgment indemnify NV against all costs and expenses incurred (including attorneys’ fees
and costs) and against all damages, losses, liabilities and expenses (including attorneys’ fees and costs) awarded against
NV by a court of competent jurisdiction, or agreed to in a written settlement agreement signed by AC, arising out of such claim.

 

    	8

    	 

    

COMPANY CONFIDENTIAL

 

 

		10.3	Enjoinment of Use. If a final judgment or administrative
ruling is obtained enjoining or charging for the use of the Licensed Patent(s) or the Licensed Product as a result of a violation
or infringement of intellectual property rights of another, AC shall at its expense procure the right to continue using the Licensed
Patent(s) and Licensed Product. If the aforementioned obligation cannot be accomplished by AC on a commercially reasonable basis,
in the event that an injunction prevents further sale or use of the Licensed Product, AC may terminate this Agreement and in such
event AC shall refund to NV all fees and royalties paid by NV to AC hereunder with regard to Licensed Products sold by NV prior
thereto as to which NV is required to refund payments.

 

		10.4	If either party receives a written claim for damages
allegedly caused by Licensed Product, such party shall promptly, and in any case within thirty [30] days thereafter, give notice
of such possible claim to the other party, and shall cooperate fully with the other party in the defense of all such claims. The
giving of such notice promptly shall be a condition precedent to the right of indemnification hereunder. No settlement or compromise
entered into without its prior written consent shall bind a party hereto or be used in any way as evidence by one party hereto
again the other.

 

Article 11: Proprietary and
confidential Nature of ‘Know-How’

 

		11.1	All Know-How to be supplied by AC to NV under the terms
of this Agreement shall remain the property of AC. NV shall acquire no rights, title or interest in any said Know-How, except
as herein specifically licensed, and, except as provided for in this Article, the Know-How will be used by NV only to exercise
the rights granted hereunder. For clarity sake and without derogating from the provisions of the preceding sentence, NV shall
not use any Know-How in the design, development, test, manufacture or Support of any product except as expressly granted the right
to do so under sub-article 2.1 above.

 

		11.2	Except as provided in this paragraph and elsewhere in
this article, NV will not disclose, either intentionally or negligently, any such Know-How nor will it permit any such Know-How
to be disclosed to or be acquired by anyone; provided, however, that NV may disclose such Know-How (i) to suppliers, contractors,
and consultants solely to the extent necessary to exploit the rights and licenses granted hereunder, and (ii) to dealers, distributors,
sales agents, bona fide customers, and potential customers as may be necessary for any sales or maintenance program, but in no
event shall such disclosures in the context of a sales or maintenance program include manufacturing information and techniques.
Any such disclosures to customers will be accompanied by a statement restricting the use of such information for maintenance and
repair purposes. NV may disclose the Know-How, including manufacturing information and techniques to its suppliers and subcontractors,
but in such cases such disclosures shall be limited to the specific needs and purposes of the contract between NV and such suppliers
or subcontractors and the use of Know-How disclosed will be limited for said specific needs and purposes. . At the termination
of this Agreement all production tooling, test equipment, jigs and molds created pursuant to the Know-How will be transferred
at no charge to AC.

 

    	9

    	 

    

COMPANY CONFIDENTIAL

 

 

		11.3	The non-disclosure agreement entered into by the parties
on November 10, 2011 shall remain in effect and continue to govern the disclosure of confidential information by one party to
the other.

 

Article 12: Duration of Agreement

 

		12.1	The Agreement shall be effective as of the Effective
Date, and the initial term of this Agreement shall extend until two years (2) years from the receipt by NV of FDA approval for
the Licensed Product or three (3) years from the ‘Effective Date’, whichever period expires earlier. In the event
that during the initial term NV sells at least 3,500 units of Pumps in the Market, then the term of this Agreement will automatically
extend for an additional three (3) years (the “Extended Term”), provided however that during the Extended Term the
rights under Paragraphs 2.1 (B) and (C) shall be on a non-exclusive basis. At the end of said Extended Term, this Agreement shall
automatically renew for successive renewal periods of twelve (12) months each provided that NV sells at least 1,000 units of Pumps
in the Market during the preceding renewal period. Thereafter, the Agreement will continue to renew automatically each year unless
one party provides the other party with prior written notice of non-renewal at least sixty (60) days before the expiration of
the then-current term. In the event this Agreement expires upon the expiration of the initial term, subject to the terms of paragraph
12.4 below, the licenses and rights granted to NV and AC hereunder shall be of no further force or effect.

 

		12.2	This Agreement and the rights of the party hereunder
forthwith may be terminated:

 

		(a)	by mutual consent of the parties in writing, or

 

		(b)	by thirty (30) days prior written notice by AC to NV,
in accordance with the provisions of sub-article 7.3 of Article 7 above, if such delay in payment shall continue un-remedied during
such notice period, or

 

		(c)	by thirty (30) days prior written notice by one party
to the other party if said other party shall create or suffer to exist any material breach of any of the terms or conditions of
this Agreement, which shall continue un-remedied during such thirty (30) day notice period,

 

		(d)	by AC at its discretion, should NV fail to attain FDA
and CE approvals within two (2) years of the Effective Date or at any other time should NV be prevented from distribution of Licensed
Product, as a result of FDA sanctions, for a period of at least 150 days.

 

		12.3	The exercise by either party of any rights of termination
pursuant to paragraph 12.2 of this Article 12 shall not affect AC’s right to be fully paid any royalties or other accrued
payment obligations which accrued prior to or after said termination, except if termination is due to the breach of AC.

 

    	10

    	 

    

COMPANY CONFIDENTIAL

 

 

		12.4	Upon expiration or termination of this Agreement, NV
shall have the right to complete and service orders previously contracted for and to accept orders based on binding offers mailed
prior to the effective date of termination or expiration. In the event NV shall complete such orders, it shall be obliged to continue
to pay AC royalties therefore, as provided in Article 7.

 

		12.5	The provisions of Articles 10 and 11 shall survive the
termination or expiration of this Agreement. NV shall, in the event of the expiration or termination of this Agreement, return
to AC all Technical Data received or reproduced under this Agreement which are in a form suitable for transmittal, and shall destroy
all other such data, and shall cease the use of the Know How and of the special tooling used in the manufacture of the Licensed
Product, and shall discontinue the manufacture and sale of the Licensed Product. Excluded from above restrictions are any and
all data, know-how, and measures which are necessary to enable NV to fulfill its guarantee, service and repair obligations vis-a-vis
all customers using previously sold Licensed Products. Additionally, at AC’s request, NV shall transfer to AC all tooling
and production jigs, test equipment and fixtures in the Licensed Product production line of NV.

 

		12.6	Nothing contained herein shall be construed to grant
any rights to NV, or to any person, firm or corporation claiming under NV, other than the rights specifically set forth in this
Agreement.

 

		12.7	Should AC desire to accept an offer from a third party
to purchase (i) all or substantially all of the intellectual property rights of AC in the Licensed Patent(s) or Licensed Products,
or (ii) all or substantially all of the stock or assets of AC, NV shall have the right of first refusal to make such purchase
from AC on the same terms as offered by such third party. AC will promptly notify NV in writing upon the receipt of any such offer,
and for this purpose, NV will have 30 days from NV’s receipt of written notice of such offer to exercise this right, and
agrees to purchase the intellectual property, stock, or assets, as the case may be, on such terms, within 30 days from NV’s
notice that it will be exercising its right of first refusal, whereupon NV will be required to make payment of the purchase price
in accordance with such third party offer or this right will terminate.

 

Article 13: Intentionally
Left Blank

 

Article 14: Remedies

 

		14.1	In the event any of the representations or warranties
by AC under Article 4 are breached or prove to be untrue or if third parties successfully prosecute a patent infringement action
against NV and/or AC regarding the ‘Licensed Product’, then AC will be responsible for the judgment in such case.

 

    	11

    	 

    

COMPANY CONFIDENTIAL

 

 

		14.2	Notwithstanding anything to the contrary in the foregoing
provisions of Article 14, in no event will either party be liable for any indirect, incidental or consequential damages of any
kind to the other party or otherwise.

 

		14.3	Except with regard to a breach of confidentiality, breach
of the Article 4 representations and warranties, infringement of intellectual property rights, or a party’s indemnification
obligations pursuant to Article 10 above, either party’s total liability to the other party under this Agreement shall be
limited to the payments paid or payable by NV to AC during the twelve-month period preceding the interposition of the claim.

 

Article 15: Notices

 

Any and all notices, payments
or statements required under this Agreement shall be made in writing and addressed as follows:

 

NanoVibronix Inc.

105 Maxess Road, Suite S124

Melville, NY 11747

 

AC Engineering

11 Netivei Am

Jerusalem, Israel 97552

 

Article 16:Miscellaneous

 

		16.1	Counterparts. This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original but all of which taken together shall constitute one
and the same Agreement.

 

		16.2	Severability. If any provision of this Agreement
is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nevertheless
continue in full force, without being impaired or invalidated in any way.

 

		16.3	Execution of Documents. Each party agrees to
execute and deliver such other documents and instruments and to take such further actions as may be reasonably necessary to fully
carry out the intent and purposes of this Agreement.

 

		16.4	Headings. The headings contained in this Agreement
have been inserted for convenience only, and in no way define or limit the scope or interpretation of the Agreement.

 

		16.5	Governing Law and Jurisdiction. This Agreement
shall be construed in accordance with the laws of the State of Israel. Any claim by any Party against the other Party hereunder
shall be brought exclusively in the courts of the State of Israel.

 

    	12

    	 

    

COMPANY CONFIDENTIAL

 

 

IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.

 

 

	AC Engineering Ltd.
	By:	/s/ Carmeli Adahan
	Name:	Carmeli Adahan
	Title:	CEO
	Date:	December 11, 2011

 

 

	NanoVibronix Inc.
	By:	/s/ Harold Jacob
	Name:	Harold Jacob
	Title:	President
	Date:	December 10, 2011

 

    	13

    	 

    

COMPANY CONFIDENTIAL

 

 

Exhibit
A

Licensed
Product Specification

 

Performance Specification for
the AC NPWT pump:

 

		1.	Reach and maintain one of selectable 6 vacuum levels:
50, 75,100,125,150.175 mm. Hg.

		2.	Vacuum levels are to be maintained at ±10mm.
Hg.

		3.	Attaining the selected vacuum level is indicated by
a double audible beep.

		4.	Vacuum levels are to be maintained when leakage is between
50 and 350 ml/minute. (Hypodermic needles 26G for max. leakage 27G x 1/2" for minimal leakage).

		5.	At steady state the system should draw no more than
250 ma current.

		6.	When a line occlusion exists, the motor speed should
be reduced to 30 RPM If vacuum keeps rising the pump should shut down and an alarm should sound, together with the occlusion LED
lighting up.

		7.	If the motor exceeds 300 RPM and the desired vacuum
level is not obtained within 30 seconds a leakage alarm and LED are activated and the system is shut down.

		8.	When the charger is plugged in for charging the charge
LED is on and a beep is sounded when charge begins. Charger disconnect during operation will result in an audible BEEP.

		9.	At end of battery charge charger LED will change color.

		10.	Low battery alarm and LED light start when battery voltage
drops below 6.5 VDC.

		11.	Intermittent mode switch results in the pump operating
5 minutes on and 2 minutes off, with intermittent LED on at all times. Pressing intermittent switch during operation stops intermittent
mode.

		12.	All key depressions respond to 2 second key activation.
Exception is the alarm silence switch, which responds with no delay.

		13.	Initial vacuum level at start is always 50 mm Hg. After
reaching 175 mm Hg. setting, depressing vacuum level switch will revert setting to 50 mm Hg.

		14.	When vacuum level is being reduced motor is rotated
at minimal speed to obtain vacuum reading.

		15.	When canister is full liquid blocks the filter —
alarm and LED should activate and motor will stop.

		16.	Alarm silence key activation stops the audible alarm
for 30 seconds.

 

AC vacuum drainage system user
instructions:

 

Press  to turn suction on/ of

		-	Obtain desired vacuum level by pressing the mm/hg key

		-	Alarm will sound when leak is present for more than
15 seconds

		-	A double signal indicates vacuum level reached

		-	System may operate either upright or laying down.

		-	Keyboard will lock after 5 minutes or by pressing the
key button.

 

    	14

    	 

    

COMPANY CONFIDENTIAL

 

 

Exhibit
B

Production
Line and Related Tasks Required of NV

 

A part of the Agreement, NV shall
take full responsibility for establishing and maintaining, either directly or through subcontractors, a production line for the
manufacture of Licensed Products.

 

Establishing and maintaining
a production line that shall include the following roles and responsibilities:

 

		1.	Procurement - handle procurement process including:
finding and negotiating with potential suppliers, placing components' purchase orders, etc.

		2.	Shipping and handling components from the relevant supplier
to NV warehouse

		3.	Inventory - maintaining sufficient inventory to meet
purchase orders and forecasts, submitted by AC.

		4.	Managing the production process, either directly or
through subcontractors, of the following elements: Silicone parts, Plastic components, Electronic circuit board and its components,
with attention given to long-lead items.

		5.	Assembling - responsibility of assembling the Licensed
Product from components to sellable product.

		6.	Quality Assurance - Implementing automatic Quality Assurance
tests for all assembled elements separately (Pump, Canister) as well as Quality Assurance tests of the entire assembled product.

		7.	Packing — For AC's orders, packaging according
to AC requirements, with AC assuming the cost of such packing.

		8.	Shipping or preparing for pickup.

		9.	Maintain ISO 9001 certification.

 

    	15

    	 

    

COMPANY CONFIDENTIAL

 

 

Exhibit
C

Production
Pricing and Special Terms

 

The price of Licensed Product
from NV to AC shall be the NV direct production costs (i.e., material costs plus per produced unit direct labor per produced unit
for manufacturing through FAT, plus a G&A load which will not exceed 10% of the combined material and direct labor costs (the
"G&A Load"), plus a 10% profit margin thereon. Every six months the parties shall review the pricing to determine
any reduction in costs due to learning curves or improvements in product and technology and adjust the price accordingly.

 

The Licensed Product which NV
will manufacture for AC will be provided initially within four (4) months from date of order, and then after six (6) months the
lead time will be reduced to 3 months, all provided that NV has an active production line. In the event the capacity of the NV
production line is insufficient to meet both NV's market requirements and the orders from AC, then until NV expands that capacity,
AC will be entitled to at least 30% of the Licensed Hardware units produced on NV's production Line against AC's orders. On the
first of each month, AC will provide NV with a running three-month forecast of its projected needs for Licensed Products over the
upcoming three months. NV shall invoice AC for Licensed Product manufactured by NV for AC upon delivery, and AC shall make payment
within forty-five (45) days of the date of invoice.

 

It is understood by NV that the
Licensed Product to be delivered to AC may require minor modifications from the NV standard product (such as labeling, packaging,
user manuals, and programming) and NV agrees to implement those modifications for AC at cost, plus the G&A Load, plus a 10%
profit margin thereon.

 

AC may continually or from time
to time observe the Production process for the Licensed Product upon written notice of at least one week.

 

    	16

    	 

    

COMPANY CONFIDENTIAL

 

 

Exhibit
D

Licensed
Patents

 

	
        1

         

        A Compact
        Vacuum Pump – (JR0040968)

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	International Procedure	
        PCT/IL02/00661

        W003/016719
	1452267	12/08/2002	 	 	 	
        US 5,466,229

        US 4,747,843

        US 5,173,033

        US 4,883,476
	Completed	 
	U. S. A.	
        10/486,940

        US 2004-028756
	1452291	12/08/2002	7,284,965	23/OCT/2007	23/4/2015	
        US 5,173,033

        US 6,135,725

        US5,021,048

        US 4,231,722
	Granted	 
	USA .-CONT	
        11/529,388

        U52007-0031268
	1686468	29/09/2006	7,758,539	20/JUL/2010	20.1.2014	
        US 4570833

        US 4828464

        US 5645540
	Granted	 
	U.S.A-CONT	
        11/896,674

        US2007-0297924
	1774991	05/09/2007	7,918,654	05.04.2011	05.10.2014	US 6315534 US4468222	Granted	 

 

The following references were
also cited in the Priority application, filed in GB 2124712

EP1045146

EP0494375

US 4842584

US 4798589

US4639245

 

	
        2

         

        Wound
        Closure and Drainage System- (JR0046587

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	International Procedure	
        IL2005/000784

        W02007/013049
	1615905	24/07/2005	 	 	 	
        US 2004/064132

        US 4,930,997

        US 4,661,093

        US 2001/029956

        WO 03/016719

        US 5,645,081

        US 2002/151826

        US 5,776,119

        US 2004/059284
	Completed	 
	U.S.A.	
        11/989,297

        US2009-0264837
	1797042	24/07/2005	 	 	 	
        US5941859

        US4108574

        US20050180868

        US4208171

        US20040015042

        US3516160
	
        In

        Examination
	Office Action received; deadline to respond is 11.1.12 extension possible until 11.4.12

 

    	17

    	 

    

COMPANY CONFIDENTIAL

 

 

	
        3

         

        Suctioning
        System, Method and Kit - (JR0047730)

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	U.S.A.	
        11/344,007

        2007-0179460
	1642628	01/02/2006	7,503,910	11/MAR/2009	17/9/2012	
        US5370610

        US5662599

        US6471982

        US5636643

        US7128735

        US 5,370,610+

        US 5,662,599+

        US 6,471,982+

        US 5,636,643+

        US 7,128,735+
	Granted	 
	International Procedure	
        IL2006/000855

        W02007/013064
	1685999	24/07/2006	 	 	 	
        GB 2,378,734

        US 5,419,687

        US 2001/029956

        DE 10215896

        US 2004/199840

        US 6,042,560
	Completed	 

 

 

	
        4

         

        Suctioning
        System, Method and Kit - (JR0050306)

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	International Procedure	
        1L2006/001287

        W02007/088530
	1710805	08/11/2006	 	 	 	
        WO 00/02016

        DE 2401643

        WO 96/05873

        EP 0156211

        US 6071267

        US 2005004534

        US 5599333

        US 2004039243

        US 2003014022

        US 3416461

        WO 03/016719
	 	Completed
	U.S.A.	
        12/223,473

        US2009-0030402
	1843192	08/11/2006	 	 	 	WO/02016	
        In

        Examination

         
	
        Office Action received;
        deadline to respond

        13.1.12 extension until 13.4.12

 

    	18

    	 

    

COMPANY CONFIDENTIAL

 

 

	
        5

         

        Vacuum
        system and kit therefore-(JR0051674)

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	
        U.S.A. –

        PROV
	60/924,268	1745470	07/5/2007	 	 	 	*	Provisional ended	 
	International Procedure	
        IL2008000624

        W02008/135997
	1801463	06/05/2008	 	 	 	 	 	Completed
	U.S.A.	12/451,335 US20100063483	1957778	06/5/2008	 	 	 	 	Published	Awaiting first Office Action

 

 

	
        6

         

        Wound
        enclosure - (JR0055047)

	Country	App. No. and Pub No.	Our Ref.	Filed	Patent No.	Date of Grant	Next Renewal	References cited	Status	Next action
	PCT	
        IL2009/000618

        W02009/156984
	1922871	23/06/2009	 	 	 	 	 	Completed
	U.S.A.	12/999,663 US20110125113	2057650	23/06/2009	 	 	 	 	 	Filed

 

    	19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]